cleminorexton

News

Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.